Veerhealth Care

Why is Veerhealth Care Ltd falling/rising?

As of 05-Aug, Veerhealth Care Ltd's stock price is at Rs. 44.03, having risen 0.89% and significantly outperforming the Sensex over various time frames. Despite a decrease in investor participation, the stock's strong performance and new 52-week high indicate bullish momentum.

As of 05-Aug, Veerhealth Care Ltd's stock price is rising, currently at Rs. 44.03, reflecting a change of 0.39 (0.89%) upwards. This upward movement is supported by several factors. Over the past week, the stock has increased by 4.36%, significantly outperforming the Sensex, which rose by only 1.19%. In the past month, Veerhealth Care has shown a remarkable gain of 35.19%, while the Sensex has only increased by 1.05%. Year-to-date, the stock has surged by 127.78%, contrasting sharply with the Sensex's decline of 7.79%. <BR><BR>Additionally, the stock reached a new 52-week high of Rs. 44.15 today, indicating strong upward momentum. It is also trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is typically a bullish sign. However, it is worth noting that there has been a decrease in investor participation, with delivery volume falling by 10.23% compared to the 5-day average. Despite this decline in participation, the overall performance of the stock remains strong, contributing to its rising price.

Which are the latest news on Veerhealth Care?

When is the next results date for Veerhealth Care Ltd?

The next results date for Veerhealth Care Ltd is 13 August 2026.

The next results date for Veerhealth Care Ltd is scheduled for 13 August 2026.

How big is Veerhealth Care?

As of 10th June, Veerhealth Care Ltd has a market capitalization of 49.00 Cr, with recent net sales of 32.49 Cr and a net profit of 0.54 Cr. The balance sheet for March 2025 shows shareholder's funds of 22.22 Cr and total assets of 33.77 Cr.

As of 10th June, Veerhealth Care Ltd has a market capitalization of 49.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Veerhealth Care reported Net Sales of 32.49 Cr and a Net Profit of 0.54 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing Shareholder's Funds of 22.22 Cr and Total Assets of 33.77 Cr.

Who are in the management team of Veerhealth Care?

The management team of Veerhealth Care includes Shruti Y Shah (Executive Director), Arvind M Shah (Independent Director), Yogesh M Shah (Chairman & Independent Director), Bhavin S Shah (Managing Director), and several other independent and non-executive directors. They oversee the company's operations and strategic direction.

The management team of Veerhealth Care includes the following members:<BR><BR>1. **Shruti Y Shah** - Executive Director<BR>2. **Arvind M Shah** - Independent Director<BR>3. **Yogesh M Shah** - Chairman & Independent Director<BR>4. **Bhavin S Shah** - Managing Director<BR>5. **Dharnendra B Shah** - Independent Director<BR>6. **Mitesh J Kuvadia** - Independent Director<BR>7. **Rony M Shah** - Company Secretary & Compliance Officer<BR>8. **Chetan H Mehta** - Non-Executive Director<BR>9. **Prakash C Shah** - Non-Executive Director<BR>10. **Nilesh Kantilal Shah** - Non-Executive Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Who are the peers of the Veerhealth Care?

Veerhealth Care's peers include Biofil Chemicals, Kabra Drugs, Vivo Bio Tech, Shelter Pharma, Vasundhara Rasy., Mangalam Drugs, Rajnish Wellness, Vista Pharma, and Sandu Pharma. Kabra Drugs shows the highest 1-year return at 86.81%, while Veerhealth Care has a 1-year return of 39.82%.

Peers: The peers of Veerhealth Care are Biofil Chemicals, Kabra Drugs, Vivo Bio Tech, Shelter Pharma, Vasundhara Rasy., Mangalam Drugs, Rajnish Wellness, Vista Pharma, and Sandu Pharma.<BR><BR>Quality Snapshot: Below Average management risk is observed at Biofil Chemicals, Kabra Drugs, Vivo Bio Tech, Mangalam Drugs, Rajnish Wellness, Vista Pharma, and Sandu Pharma, while Average management risk is found at Shelter Pharma and Rajnish Wellness. Good management risk is noted at Vasundhara Rasy. Excellent growth is seen at Kabra Drugs, while Average growth is present at Veerhealth Care and Shelter Pharma. Below Average growth is reported at Biofil Chemicals, Vivo Bio Tech, Mangalam Drugs, Rajnish Wellness, Vista Pharma, and Sandu Pharma, and the rest. Good capital structure is noted at Biofil Chemicals, Shelter Pharma, Veerhealth Care, and Vasundhara Rasy., while Below Average capital structure is found at Kabra Drugs, Vivo Bio Tech, Mangalam Drugs, Rajnish Wellness, Vista Pharma, and Sandu Pharma.<BR><BR>Return Snapshot: Kabra Drugs has the highest 1-year return at 86.81%, while Mangalam Drugs has the lowest at -65.43%. Veerhealth Care's 1-year return of 39.82% is significantly higher than Mangalam Drugs but lower than Kabra Drugs. Additionally, the six-month return is negative for Kabra Drugs, Vivo Bio Tech, Mangalam Drugs, Rajnish Wellness, Vista Pharma, and Sandu Pharma.

What does Veerhealth Care do?

Veerhealth Care Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 17 Cr and a net profit of 0 Cr for the quarter ending March 2026. The company, originally incorporated in 1992, has a market cap of INR 49 Cr and key metrics including a P/E ratio of 58.00.

Overview:<BR>Veerhealth Care Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated in 1992 as Niyati Leasing Limited, later changing its name to Niyati Industries Limited in 1998, and finally to Veerhealth Care Limited in May 2013. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 17 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>- Market-cap: INR 49 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 58.00<BR>- Industry P/E: 21<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.18<BR>- Return on Equity: 3.71%<BR>- Price to Book: 2.14<BR><BR>Contact Details:<BR>Address: 629-A 1st Floor Gazdar House, JSS Marg Nr Kalbadevi Post Off Mumbai Maharashtra : 400002<BR>Tel: 91-22-22018582<BR>Email: info@veerhealthcare.net<BR>Website: http://www.veerhealthcare.net

Should I buy, sell or hold Veerhealth Care Ltd?

Are Veerhealth Care Ltd latest results good or bad?

Veerhealth Care Ltd's latest results show strong revenue growth with a 130.85% increase in net sales quarter-on-quarter, but the company reported a net loss of ₹0.35 crores and a significant decline in profit margins, indicating challenges in maintaining profitability. Investors should approach with caution due to these mixed signals.

Veerhealth Care Ltd's latest results present a mixed picture. On one hand, the company achieved a remarkable 130.85% increase in net sales quarter-on-quarter, reaching ₹16.76 crores, and a significant 198.22% increase year-on-year. This growth indicates strong topline momentum, which is a positive sign for the company.<BR><BR>However, the financial performance is marred by a net loss of ₹0.35 crores in Q4 FY26, a stark contrast to the profit of ₹0.40 crores reported in the previous quarter. This loss, coupled with a drastic decline in profit margins—operating margin fell to 4.36% from 17.08%—raises concerns about the company's ability to convert revenue growth into sustainable profits. Additionally, the extraordinary tax charge leading to an effective tax rate of 294.44% further complicates the earnings picture, suggesting potential issues with earnings quality.<BR><BR>Overall, while the revenue growth is impressive, the inability to maintain profitability and the significant margin compression indicate that investors should approach Veerhealth Care with caution. The results highlight both potential and challenges, making it a high-risk investment at this stage.

How has been the historical performance of Veerhealth Care?

Veerhealth Care's historical performance shows net sales growth from 9.63 Cr in Mar'22 to 16.67 Cr in Mar'25, but profitability has fluctuated, with profit after tax declining from 1.58 Cr in Mar'23 to 0.39 Cr in Mar'25. Total assets increased significantly, while cash flow from operating activities dropped to 0.00 Cr in Mar'25.

Answer:<BR>The historical performance of Veerhealth Care shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Veerhealth Care's net sales have increased from 9.63 Cr in Mar'22 to 16.67 Cr in Mar'25, indicating a positive growth trajectory. Total operating income followed a similar pattern, rising from 9.63 Cr in Mar'22 to 16.67 Cr in Mar'25. The company's total expenditure also grew, reaching 16.21 Cr in Mar'25 from 10.45 Cr in Mar'22. Operating profit (PBDIT) fluctuated, peaking at 2.00 Cr in Mar'24 before dropping to 1.68 Cr in Mar'25. Profit before tax showed variability, with a notable increase to 1.28 Cr in Mar'24 but declining to 0.51 Cr in Mar'25. Profit after tax was 0.39 Cr in Mar'25, down from 1.58 Cr in Mar'23. The company's total assets increased significantly from 20.15 Cr in Mar'22 to 33.77 Cr in Mar'25, while total liabilities also rose from 20.15 Cr to 33.77 Cr in the same period. Cash flow from operating activities was 0.00 Cr in Mar'25, contrasting with 2.00 Cr in Mar'24, while cash flow from investing activities showed a negative trend at -8.00 Cr in Mar'25. Overall, Veerhealth Care's financial performance reflects both growth in sales and assets, alongside challenges in profitability and cash flow management.

Who are the top shareholders of the Veerhealth Care?

The top shareholder of Veerhealth Care is Yogesh Mahasuklal Shah, with an 11.03% stake, followed by public shareholder Deval Nilay Shah at 2.68%. Individual investors collectively own 57.92% of the shares, with no mutual funds or foreign institutional investors involved.

The top shareholders of Veerhealth Care include Yogesh Mahasuklal Shah, who holds the highest stake at 11.03%. The highest public shareholder is Deval Nilay Shah, with a holding of 2.68%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 57.92% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

Is Veerhealth Care overvalued or undervalued?

As of February 13, 2025, Veerhealth Care is considered overvalued with a PE ratio of 30.00 and an EV to EBITDA of 33.75, despite recent strong stock performance, indicating a shift in sentiment from very expensive to risky compared to peers like Elitecon International and Lloyds Enterprises.

As of 13 February 2025, Veerhealth Care's valuation grade has moved from very expensive to risky, indicating a shift in investor sentiment. The company is currently assessed as overvalued. Key ratios include a PE ratio of 30.00, an EV to EBITDA of 33.75, and a ROE of 1.76%. <BR><BR>In comparison to its peers, Veerhealth Care's PE ratio is significantly lower than that of Elitecon International, which stands at 131.08, and also lower than Lloyds Enterprises at 156.59. However, it is on par with MMTC, which has a PE ratio of 119.39. Notably, the company's recent stock performance has outpaced the Sensex in the short term, with a 1-week return of 9.80% compared to the Sensex's 1.43%. This suggests some short-term investor interest, but the overall valuation still leans towards overvaluation given the broader financial metrics.

What is the technical trend for Veerhealth Care?

As of May 12, 2025, Veerhealth Care shows a mildly bearish trend overall, with mixed indicators suggesting short-term weakness despite a current price of 16.47, which is above the previous close of 15.00.

As of 12 May 2025, the technical trend for Veerhealth Care has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD indicates a mildly bearish stance. The moving averages on a daily basis are also mildly bearish, suggesting short-term weakness. Bollinger Bands show a bullish signal on the weekly timeframe but are mildly bearish monthly. The KST reflects a mildly bullish trend weekly while being mildly bearish monthly. Overall, the indicators present a mixed picture, with a slight bearish bias prevailing in the longer term. The current price of 16.47 is above the previous close of 15.00, but the stock has underperformed significantly over the past year. The overall stance is mildly bearish with moderate strength.

What is the bonus history of the Veerhealth Care?

Veerhealth Care recently issued a 1:1 bonus share on September 22, 2023, meaning shareholders received an additional share for each share held. The record date for this bonus was also September 22, 2023.

Veerhealth Care has a recent bonus history that includes a 1:1 bonus issue announced with an ex-date of September 22, 2023. This means that for every share held, shareholders received an additional share. The record date for this bonus was also September 22, 2023. If you have any more questions about Veerhealth Care or need further details, feel free to ask!

Has Veerhealth Care declared dividend?

No Dividend History Available